Table 3. Complete response to nausea/vomiting according to sociodemographic, clinical, and treatment phase variables. Belo Horizonte (MG), Brazil, 2015.
| Complete Nausea/vomiting response | |||||||
|---|---|---|---|---|---|---|---|
| Acute phase | Late phase | Total phase | |||||
| Total number of participants (%) | pa | Total number of participants (%) | pa | Total number of participants (%) | pa | ||
| Gender | |||||||
| Female | 172 (67.4) | 0.692 | 173 (38.7) | 0.144 | 173 (37.0) | 0.451 | |
| Male | 96 (69.8) | 96 (47.9) | 96 (41.7) | ||||
| Age group | |||||||
| ≤ 49 | 84 (69.0) | 0.317 | 85 (35.3) | 0.085 | 85 (32.9) | 0.024 | |
| 50–64 | 120 (64.2) | 120 (40.8) | 120 (35.0) | ||||
| ≥ 65 | 64 (75.0) | 64 (53.1) | 64 (53.1) | ||||
| Marital status | |||||||
| Married | 137 (67.2) | 0.326 | 137 (37.2) | 0.363 | 137 (35.0) | 0.242 | |
| Single | 59 (74.6) | 59 (47.5) | 59 (44.1) | ||||
| Divorced | 41 (58.5) | 42 (42.9) | 42 (33.3) | ||||
| Widow/widower | 31 (74.2) | 31 (51.6) | 31 (51.6) | ||||
| Schooling (years) | |||||||
| Illiterate | 22 (59.1) | 0.637 | 22 (40.9) | 0.681 | 22 (40.9) | 0.803 | |
| 4 | 106 (67.0) | 106 (44.3) | 106 (40.6) | ||||
| 5–8 | 61 (75.4) | 61 (42.6) | 61 (41.0) | ||||
| 9–12 | 59 (66.1) | 60 (35.0) | 60 (31.7) | ||||
| ≥ 13 | 17 (6.4) | 17 (52.9) | 17 (41.2) | ||||
| Stage | |||||||
| I | 19 (73.7) | 0.387 | 19 (36.8) | 0.260 | 19 (36.8) | 0.670 | |
| II | 50 (58.0) | 50 (32.0) | 50 (32.0) | ||||
| III | 103 (68.9) | 104 (43.3) | 104 (39.4) | ||||
| IV | 77 (71.4) | 77 949.4) | 77 (42.9) | ||||
| Metastasis | |||||||
| Yes | 119 (70.6) | 0.469 | 119 (42.0) | 0.998 | 119 (38.7) | 0.999 | |
| No | 149 (66.4) | 150 (42.0) | 150 (38.7) | ||||
| Alcohol | |||||||
| Currently | 35 (80.0) | 0.271 | 35 (42.9) | 0.782 | 35 (42.9) | 0.663 | |
| Former smoker | 128 (67.2) | 128 (39.8) | 128 (35.9) | ||||
| Never | 105 (65.7) | 106 (44.3) | 106 (40.6) | ||||
| Tobacco | |||||||
| Currently | 31 (41.9) | 0.002 | 31 (29.0) | 0.086 | 31 (22.6) | 0.051 | |
| Former smoker | 119 (75.6) | 119 (48.7) | 119 (51.9) | ||||
| Never smoked | 118 (67.8) | 119 (38.7) | 119 (36.1) | ||||
| Chemotherapy costing | |||||||
| SUS | 252 (67.6) | 0.476 | 253 (41.5) | 0.648 | 253 (38.3) | 0.605 | |
| Health insurance plan | 13 (76.9) | 13 (46.2) | 13 (38.5) | ||||
| Access to antiemetics at home | |||||||
| Purchased/did not purchase | 157 (65.0) | 0.165 | 157 (40.1) | 0.460 | 157 (37.6) | 0.666 | |
| Did not purchase | 111 (73.0) | 112 (44.6) | 112 (40.2) | ||||
| Hospital | |||||||
| Hospital 1 | 69 (84.0) | 0.015 | 69 (47.8) | 0.642 | 69 (47.8) | 0.513 | |
| Hospital 2 | 139 (64.7) | 140 (46.4) | 140 (40.0) | ||||
| Hospital 3 | 90 (68.8) | 90 (41.1) | 90 (40.0) | ||||
| Emetogenic chemotherapy | |||||||
| Hec | 151 (64.2) | 0.106 | 152 (36.8) | 0.05 | 152 (32.2) | 0.014 | |
| Mec | 117 (73.5) | 117 (48.7) | 117 (47.0) | ||||
| Acute phase antiemetic | |||||||
| Simplified scheme | 7 (71.4) | 0.820 | 7 (71.4) | 0.071 | 7 (57.1) | 0.209 | |
| Dexamethasone + ondansetron | 200 (67.0) | 201 (38.3) | 201 (35.8) | ||||
| Dexamethasone + Ondansetron + other | 61 (72.1) | 61 (51.0) | 61 (46.0) | ||||
| Late phase antiemetic | |||||||
| Ondansetrona and others | – | 78 (38.5) | 0.505 | 78 (30.8) | 0.313 | ||
| Dexamethasone + Ondansetron + other antiemetics | – | 73 (43.8) | 73(42.5) | ||||
| Other antiemeticsb | – | 34 (29.4) | 34 (29.4) | ||||
| Dexamethasone + ondansetron | – | 31 (41.9) | 31 (35.5) | ||||
| Ondansetron | – | 16 (37.5) | 16 (37.5) | ||||
| Dexamethasone and others | – | 7 (71.4) | 7 (71.4) | ||||
| Dexamethasone | – | 2 (50.0) | 2 (50.0) | ||||
SUS: Unified Health System; HEC: high emetogenic chemotherapy; MEC: moderate emetogenic chemotherapy.
a
Fisher's exact test or chi-square test
b
other antiemetics: h2 antagonist (diphenhydramine, dimenhydrinate, bromopride, omeprazole, ranitidine) and dopamine receptor antagonist (metoclopramide).